Replies to post #122224 on Biotech Values

[flatlander_60048]

quote
___________________________________________________________________
I'd be curious if that was intentionally omitted for obvious reasons.
____________________________________________________________________

Could be. They indicate that tolerability is being evaluated however, it would seem that they could provide a summary of what percentage of the subjects completed the trial.

Thanks

FL

[genisi]

I think the potential market share for REGN's Arcalyst in gout flare prophylaxis remains small even if Ilaris is out of the game.